Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Sera Prognostics Inc's Business Segments
Sera Prognostics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2026
Reportable Segments
1
Largest Segment
Single Reporting Segment
Total Revenue
$ 0
Regions Reported
-
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/SERA/segments
https://api.csimarket.com/api/v1/companies/SERA/geographic
https://api.csimarket.com/api/v1/companies/SERA/exposure
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Revenue Share by Reportable Segment - Q3 FY2026
- Single Reporting Segment100%
Revenue by Reportable Segment - Q3 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reporting Segment | $ 0 | 100% |
Description of Sera Prognostics Inc
Sera Prognostics Inc. is a biotechnology company that specializes in developing and commercializing innovative diagnostic tests for women's health. The company's primary focus is on improving pregnancy outcomes and treating pregnancy-related complications.
Founded in 2008 and headquartered in Salt Lake City, Utah, Sera Prognostics aims to bridge the gap in reproductive medicine through its groundbreaking biomarker-based tests. The company's primary product is the PreTRM® Test, which is designed to predict a woman's individualized risk for preterm birth. Preterm birth is one of the leading causes of infant mortality and long-term disability, and the PreTRM Test helps physicians identify women at high risk, allowing for targeted interventions to prevent preterm birth.
The PreTRM Test is based on the measurement of specific proteins in the blood. These proteins serve as biomarkers that reflect the underlying inflammatory processes occurring in a pregnant woman's body, which are associated with preterm birth. By analyzing these biomarkers, the test provides a quantitative risk score that helps clinicians predict the risk of preterm birth occurring before 37 weeks of gestation.
Sera Prognostics conducts extensive clinical research and collaborates with renowned academic institutions to validate the accuracy and clinical utility of its tests. The company has amassed a robust database of biomarker data from thousands of pregnant women, further enhancing the accuracy and reliability of its predictive models.
The PreTRM Test is performed by drawing a blood sample from the pregnant woman as early as 19 weeks of gestation. The sample is then sent to Sera Prognostics' state-of-the-art laboratory for analysis using advanced proteomic techniques. The results are typically available within a week, providing timely information to guide clinical decision-making.
In addition to its primary focus on preterm birth, Sera Prognostics is also actively engaged in research and development of innovative diagnostic tests for other pregnancy-related complications, such as preeclampsia and fetal growth restriction. By applying its expertise in biomarker discovery and validation, the company aims to address the unmet medical needs in women's health and improve outcomes for both mothers and babies.
Sera Prognostics operates with a strong commitment to quality and regulatory compliance. The company holds several certifications, including ISO 13485, demonstrating adherence to international standards for medical device quality management systems. This commitment extends to ongoing clinical studies and collaborations with healthcare providers to ensure that its tests have a positive impact on patient outcomes.
Overall, Sera Prognostics Inc. is a pioneering biotechnology company dedicated to revolutionizing women's healthcare through the development and commercialization of innovative diagnostic tests. By leveraging advanced biomarker technology, the company is forging new ground in predicting and preventing pregnancy-related complications, ultimately aiming to improve the health and well-being of mothers and babies.
Founded in 2008 and headquartered in Salt Lake City, Utah, Sera Prognostics aims to bridge the gap in reproductive medicine through its groundbreaking biomarker-based tests. The company's primary product is the PreTRM® Test, which is designed to predict a woman's individualized risk for preterm birth. Preterm birth is one of the leading causes of infant mortality and long-term disability, and the PreTRM Test helps physicians identify women at high risk, allowing for targeted interventions to prevent preterm birth.
The PreTRM Test is based on the measurement of specific proteins in the blood. These proteins serve as biomarkers that reflect the underlying inflammatory processes occurring in a pregnant woman's body, which are associated with preterm birth. By analyzing these biomarkers, the test provides a quantitative risk score that helps clinicians predict the risk of preterm birth occurring before 37 weeks of gestation.
Sera Prognostics conducts extensive clinical research and collaborates with renowned academic institutions to validate the accuracy and clinical utility of its tests. The company has amassed a robust database of biomarker data from thousands of pregnant women, further enhancing the accuracy and reliability of its predictive models.
The PreTRM Test is performed by drawing a blood sample from the pregnant woman as early as 19 weeks of gestation. The sample is then sent to Sera Prognostics' state-of-the-art laboratory for analysis using advanced proteomic techniques. The results are typically available within a week, providing timely information to guide clinical decision-making.
In addition to its primary focus on preterm birth, Sera Prognostics is also actively engaged in research and development of innovative diagnostic tests for other pregnancy-related complications, such as preeclampsia and fetal growth restriction. By applying its expertise in biomarker discovery and validation, the company aims to address the unmet medical needs in women's health and improve outcomes for both mothers and babies.
Sera Prognostics operates with a strong commitment to quality and regulatory compliance. The company holds several certifications, including ISO 13485, demonstrating adherence to international standards for medical device quality management systems. This commitment extends to ongoing clinical studies and collaborations with healthcare providers to ensure that its tests have a positive impact on patient outcomes.
Overall, Sera Prognostics Inc. is a pioneering biotechnology company dedicated to revolutionizing women's healthcare through the development and commercialization of innovative diagnostic tests. By leveraging advanced biomarker technology, the company is forging new ground in predicting and preventing pregnancy-related complications, ultimately aiming to improve the health and well-being of mothers and babies.
Sera Prognostics Inc. is a biotechnology company focused on advancing womens health, particularly in the area of pregnancy. The company is known for leveraging proprietary biomarker technologies to develop products and services aimed at improving pregnancy outcomes. Below is an extensive description of the segments, products, and services offered by Sera Prognostics.
Segments
1. Maternal Health:
Sera Prognostics operates primarily within the maternal health segment, focusing on diagnosing and predicting pregnancy-related complications. This segment encompasses various risks that pregnancies may face, including preterm birth and other adverse events.
2. Diagnostics:
Within the diagnostics segment, Sera develops tests that utilize biomarker analysis to provide insights into maternal and fetal health. This segment is crucial for guiding clinical decisions during pregnancy.
3. Research and Development:
The research and development segment focuses on the ongoing innovation of new tests and products. Sera invests in scientific studies and collaborates with healthcare professionals to explore new biomarkers and methods for assessing pregnancy risks.
4. Partnerships and Collaborations:
Sera engages in partnerships with healthcare providers, research institutions, and other organizations to enhance its product offerings and leverage expertise in the field of obstetrics and gynecology.
Products
1. PreTRM® Test:
The flagship product of Sera Prognostics is the PreTRM® test, designed to assess the risk of preterm birth in pregnant women. The test analyzes specific biomarkers in maternal blood to evaluate the likelihood of delivering prematurely. It provides healthcare providers with critical information that can aid in the management of pregnancy and interventions that may improve outcomes.
2. Laboratory Services:
Sera offers comprehensive laboratory services to process and analyze samples for its tests. These services include sample collection, processing, and reporting of results to healthcare providers. The laboratory adheres to high standards of quality and compliance to ensure reliable outcomes.
3. Biomarker Panels:
Sera develops panels of biomarkers that can be employed to assess various aspects of pregnancy health. These panels are customizable and can be tailored based on specific patient demographics or risk factors.
4. Consultative Services:
Apart from diagnostic testing, Sera provides consultative services to healthcare professionals. This includes assistance in interpreting test results and integrating findings into patient management plans.
Services
1. Patient and Provider Education:
Sera offers educational resources and support for both patients and healthcare providers. This includes information about the importance of prenatal testing, understanding biomarkers, and how to interpret results effectively.
2. Clinical Support:
Sera provides clinical support to obstetricians and healthcare practitioners, helping them understand the implications of testing results and offering guidance on managing high-risk pregnancies.
3. Clinical Trials and Research Services:
The company engages in clinical trials to validate its testing methodologies and explore further applications of its technologies. Research services may include collaboration with academic institutions to study pregnancy health.
4. Regulatory Support:
Sera assists healthcare providers with navigating the regulatory landscape related to maternal health diagnostics. This can include support related to compliance, reimbursement, and the integration of new technologies into clinical practice.
5. Data Analytics:
Sera Prognostics may also offer analytics services to provide insights from the data gathered during testing. This could involve generating reports that help in tracking maternal and fetal health over time.
In summary, Sera Prognostics Inc. provides a broad spectrum of services and products primarily aimed at improving maternal health through the use of advanced biomarker technologies. The companys focus on accurate diagnostics and patient-centered care positions it as a significant player in the field of maternal-fetal medicine.
Segments
1. Maternal Health:
Sera Prognostics operates primarily within the maternal health segment, focusing on diagnosing and predicting pregnancy-related complications. This segment encompasses various risks that pregnancies may face, including preterm birth and other adverse events.
2. Diagnostics:
Within the diagnostics segment, Sera develops tests that utilize biomarker analysis to provide insights into maternal and fetal health. This segment is crucial for guiding clinical decisions during pregnancy.
3. Research and Development:
The research and development segment focuses on the ongoing innovation of new tests and products. Sera invests in scientific studies and collaborates with healthcare professionals to explore new biomarkers and methods for assessing pregnancy risks.
4. Partnerships and Collaborations:
Sera engages in partnerships with healthcare providers, research institutions, and other organizations to enhance its product offerings and leverage expertise in the field of obstetrics and gynecology.
Products
1. PreTRM® Test:
The flagship product of Sera Prognostics is the PreTRM® test, designed to assess the risk of preterm birth in pregnant women. The test analyzes specific biomarkers in maternal blood to evaluate the likelihood of delivering prematurely. It provides healthcare providers with critical information that can aid in the management of pregnancy and interventions that may improve outcomes.
2. Laboratory Services:
Sera offers comprehensive laboratory services to process and analyze samples for its tests. These services include sample collection, processing, and reporting of results to healthcare providers. The laboratory adheres to high standards of quality and compliance to ensure reliable outcomes.
3. Biomarker Panels:
Sera develops panels of biomarkers that can be employed to assess various aspects of pregnancy health. These panels are customizable and can be tailored based on specific patient demographics or risk factors.
4. Consultative Services:
Apart from diagnostic testing, Sera provides consultative services to healthcare professionals. This includes assistance in interpreting test results and integrating findings into patient management plans.
Services
1. Patient and Provider Education:
Sera offers educational resources and support for both patients and healthcare providers. This includes information about the importance of prenatal testing, understanding biomarkers, and how to interpret results effectively.
2. Clinical Support:
Sera provides clinical support to obstetricians and healthcare practitioners, helping them understand the implications of testing results and offering guidance on managing high-risk pregnancies.
3. Clinical Trials and Research Services:
The company engages in clinical trials to validate its testing methodologies and explore further applications of its technologies. Research services may include collaboration with academic institutions to study pregnancy health.
4. Regulatory Support:
Sera assists healthcare providers with navigating the regulatory landscape related to maternal health diagnostics. This can include support related to compliance, reimbursement, and the integration of new technologies into clinical practice.
5. Data Analytics:
Sera Prognostics may also offer analytics services to provide insights from the data gathered during testing. This could involve generating reports that help in tracking maternal and fetal health over time.
In summary, Sera Prognostics Inc. provides a broad spectrum of services and products primarily aimed at improving maternal health through the use of advanced biomarker technologies. The companys focus on accurate diagnostics and patient-centered care positions it as a significant player in the field of maternal-fetal medicine.